Intervention Protocol

You have free access to this content

Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants

  1. Wes Onland1,*,
  2. Anne PMC De Jaegere1,
  3. Martin Offringa2,
  4. Anton van Kaam3

Editorial Group: Cochrane Neonatal Group

Published Online: 29 JAN 2014

Assessed as up-to-date: 18 JUN 2013

DOI: 10.1002/14651858.CD010941


How to Cite

Onland W, De Jaegere APMC, Offringa M, van Kaam A. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010941. DOI: 10.1002/14651858.CD010941.

Author Information

  1. 1

    Emma Children's Hospital AMC, University of Amsterdam, Department of Neonatology, Amsterdam, Netherlands

  2. 2

    Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, ON, Canada

  3. 3

    Emma Children's Hospital AMC, University of Amsterdam, Department of Neonatology, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

*Wes Onland, Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, H3-144, Emma Children's Hospital, Amsterdam, Netherlands. W.Onland@amc.uva.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 29 JAN 2014

SEARCH

References

Additional references

  1. Additional references
  2. References to other published versions of this review
AAP 2002
Bancalari 2006
Bloomfield 1998
  • Bloomfield FH, Knight DB, Harding JE. Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial. Journal of Pediatrics 1998;133(3):395-400. [PUBMED: 9738724]
Brozanski 1995
  • Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. Journal of Pediatrics 1995;126(5 Pt 1):769-76. [PUBMED: 7752005]
Carlton 1997
  • Carlton DP, Albertine KH, Cho SC, Lont M, Bland RD. Role of neutrophils in lung vascular injury and edema after premature birth in lambs. Journal of Applied Physiology 1997;83(4):1307-7.
CDTG 1991
  • Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics 1991;88(3):421-7.
Cheong 2013
  • Cheong JL, Anderson P, Roberts G, Duff J, Doyle LW. Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia. Archives of Disease in Childhood. Fetal and Neonatal Edition 2013;98(1):F32-6. [PUBMED: 22684163]
Coalson 2006
Costeloe 2012
  • Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ (Clinical research ed.) 2012;345:e7976. [PUBMED: 23212881]
Doyle 2005
  • Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115(3):655-61. [PUBMED: 15741368]
Doyle 2010
  • Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(2):111-7. [PUBMED: 20150750]
Durand 1995
  • Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 1995;95(4):584-90.
Ehrenkranz 2005
  • Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116(6):1353-60. [PUBMED: 16322158]
Ferreira 2000
Halliday 2001
Halliday 2003a
  • Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001146]
Halliday 2003b
  • Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001144]
Halliday 2003c
  • Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001145.pub2]
Halliday 2009
  • Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001145.pub2]
Halliday 2010
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 20. Available from www.cochrane-handbook.org.
Hozo 2005
  • Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology 2005;5:13. [PUBMED: 15840177]
Huang 2007
Husain 1998
Jobe 1999
Jobe 2001
  • Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1723-9.
Kaempf 2003
  • Kaempf JW, Campbell B, Sklar RS, Arduza C, Gallegos R, Zabari M, et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics 2003;111(4 Pt 2):e534-41.
Karemaker 2006
  • Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatric Research 2006;60(6):745-50. [PUBMED: 17065571]
Lodygensky 2005
  • Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005;116(1):1-7. [PUBMED: 15995023]
Majnemer 2000
  • Majnemer A, Riley P, Shevell M, Birnbaum R, Greenstone H, Coates AL. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Developmental Medicine and Child Neurology 2000;42(1):53-60. [PUBMED: 10665976]
Northway 1967
  • Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. The New England Journal of Medicine 1967;276(7):357-68. [PUBMED: 5334613]
O'Brodovich 1985
  • O'Brodovich HM, Mellins RB. Bronchopulmonary dysplasia. Unresolved neonatal acute lung injury. American Review of Respiratory Disease 1985;132(3):694-709. [PUBMED: 3898946]
O'Shea 1999
  • O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104(1 Pt 1):15-21.
Onland 2009
  • Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009;123(1):367-77. [PUBMED: 19117904]
Rademaker 2007
  • Rademaker KJ, Uiterwaal CS, Groenendaal F, Venema MM, van Bel F, Beek FJ, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. Journal of Pediatrics 2007;150(4):351-7. [PUBMED: 17382109]
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Schmidt 2008
  • Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology 2008;93(4):284-7. [PUBMED: 18525211]
Shinwell 2003
  • Shinwell ES, Karplus M, Bader D, Dollberg S, Gur I, Weintraub Z, et al. Neonatologists are using much less dexamethasone. Archives of Disease in Childhood. Fetal and Neonatal Edition 2003;88(5):F432-3.
Shinwell 2007
  • Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birth weight infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 2007;92(1):F30-3.
Short 2007
  • Short EJ, Kirchner HL, Asaad GR, Fulton SE, Lewis BA, Klein N, et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Archives of Pediatrics and Adolescent Medicine 2007;161(11):1082-7.
Stoll 2010
  • Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126(3):443-56.
Tuor 1995
  • Tuor UI, Chumas PD, Del Bigio MR. Prevention of hypoxic-ischemic damage with dexamethasone is dependent on age and not influenced by fasting. Experimental Neurology 1995;132(1):116-22. [PUBMED: 7720820]
van der Heide-Jalving 2003
  • van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, Bakker JM, Wiegant VM, Heijnen CJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone?. Acta Paediatrica (Oslo, Norway: 1992) 2003;92(7):827-35. [PUBMED: 12892163]
Walsh 2005
  • Walsh MC, Morris BH, Wrage LA, Vohr BR, Poole WK, Tyson JE, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. Journal of Pediatrics 2005;146(6):798-804. [PUBMED: 15973322]
Walsh 2006
  • Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118(5):e1328-35.
Watterberg 2007
  • Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007;120(1):40-8. [PUBMED: 17606560]
Watterberg 2010
Yeh 1997
  • Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997;100(4):E3.
Yeh 1998
Yoder 2009
  • Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009;124(2):673-9. [PUBMED: 19620192]

References to other published versions of this review

  1. Additional references
  2. References to other published versions of this review
Onland 2008
  • Onland W, De Jaegere AP, Offringa M, van Kaam AH. Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics 2008;122(1):92-101. [PUBMED: 18595991]